02/13/2026
📢 Major Update in Women’s Health
On February 12, 2026, the FDA approved label changes for several menopausal hormone therapy products — removing long-standing boxed warnings after a comprehensive scientific review.
The first therapies updated include:
• Prometrium
• Divigel
• Cenestin
• Enjuvia
• Estring
• Bijuva
Current evidence shows that women who start hormone therapy within 10 years of menopause (typically under age 60) may see reduced fracture risk, lower overall mortality, and meaningful symptom relief.
Medicine evolves. Guidance evolves.
Women deserve accurate, up-to-date information.
If you’ve been unsure about HRT because of older warnings, it may be worth revisiting the conversation. I offer free consults to review your individual risk and options.
— Mallory Jones, FNP-BC
Lighthouse EverLucent Health™.
Curated by Smartbrief. The FDA has removed boxed warnings related to cardiovascular disease, breast cancer and probable dementia from six hormone replacement therapies after a review of the latest evidence. The label updates apply to progesterone, estradiol gel, synthetic conjugated estrogens...